| Literature DB >> 31851771 |
Claudio Andreetti1, Camilla Poggi2, Mohsen Ibrahim1, Antonio D'Andrilli1, Giulio Maurizi1, Matteo Tiracorrendo1, Valentina Peritore1, Erino Angelo Rendina1,3, Federico Venuta2,3, Marco Anile2, Andreina Pagini2, Giovanni Natale4, Mario Santini4, Alfonso Fiorelli4.
Abstract
BACKGROUND: Tumor with adjacent lobe invasion (T-ALI) is an uncommon condition. Controversy still exists regarding the optimal resection of adjacent lobe invasion, and the prognostic value in relation to fissure integrity at the tumor invasion point. The aims of this paper were to evaluate the prognosis of T-ALI with regard to fissure integrity, and type of resection.Entities:
Keywords: Adjacent lobe; fissure integrity; lung cancer; pleural invasion; surgery
Year: 2019 PMID: 31851771 PMCID: PMC6996991 DOI: 10.1111/1759-7714.13217
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Figure 1Radiological and pathological findings of T‐ALI‐D tumor. (a) Computed tomography scan of the chest showed adenocarcinoma of the middle lobe that invaded the apical segment (S6) of the lower lobe through a fissure that was fused in some areas (complete fissure: blue arrows; incomplete fissure: red arrows). (b) Pathological studies showed that tumor (*) of middle lobe (**) invaded S6 of the lower lobe (***) through an incomplete fissure point (black line: tumor; yellow line: middle lobe; green line: S6 of lower lobe; hematoxylin and eosin staining; 40× magnification).
Figure 2Radiological and pathological findings of T‐ALI‐A tumor. (a) Computed tomography scan of the chest showed squamous cell carcinoma of the left upper lobe that invaded the apical segment (S6) of the lower lobe across a complete fissure (blue arrows). The patient underwent upper lobectomy plus S6 segmentectomy of the lower lobe. (b) Pathological studies showed that tumor (*) of upper lobe (**) invaded S6 of lower lobe (***) through complete fissure point (black line: tumor; blue line: upper lobe; red line: S6 of lower lobe; hematoxylin and eosin staining; 40× magnification).
Study population
| Variable | All | T‐ALI‐A | T‐ALI‐D |
|
|---|---|---|---|---|
| Number of patients (%) | 135 | 98 (72%) | 37 (38%) | — |
| Age (year‐old) | 68 ± 3,5 | 67 ± 1.8 | 68 ± 2.8 | 0.67 |
| Sex (male) | 97 (72%) | 70 (71%) | 27 (73%) | 0.85 |
| Type of resection | ||||
|
Pneumonectomy | 23 (17%) | 18 (18%) | 5 (13%) | 0.27 |
|
Bilobectomy | 42 (31%) | 32 (33%) | 10 (27%) | |
|
Lobectomy + wedge | 45 (33%) | 35 (36%) | 10 (27%) | |
|
Lobectomy + segmentectomy | 25 (18%) | 13 (13%) | 12 (33%) | |
| Histology | 0.54 | |||
|
Squamous cell carcinoma | 71 (53%) | 50 (51%) | 21 (56%) | |
|
Adenocarcinoma | 53 (39%) | 40 (41%) | 13 (35%) | |
|
Large cell carcinoma | 11 (8%) | 8 (8%) | 3 (9%) | |
| Main location + ALI | 0.77 | |||
|
RUL + RML | 47 (35%) | 35 (36%) | 12 (32%) | |
|
RML + RLL | 20 (15%) | 13 (13%) | 7 (19%) | |
|
RUL + RLL | 29 (21%) | 21 (21%) | 8 (22%) | |
|
LUL + LLL | 39 (29%) | 29 (30%) | 10 (27%) | |
| pTumor size | 4.8 ± 1.3 | 4.7 ± 1.9 | 4.8 ± 1,1 | 0.49 |
|
pT1 (≤3 cm) | 25 (18%) | 19 (19%) | 6 (16%) | |
|
pT2 (>3 to 5 cm) | 44 (33%) | 32 (33%) | 12 (32%) | |
|
pT3 (>5 to 7 cm) | 52 (39%) | 38 (39%) | 14 (39%) | |
|
pT4 (>7 cm) | 14 (10%) | 9 (9%) | 5 (13%) | |
| pN status | 0.004 | |||
|
pN0 | 96 (71%) | 63 (64%) | 33 (90%) | |
|
pN1 | 15 (11%) | 13 (13%) | 2 (5%) | |
|
pN2 | 24 (18%) | 22 (23%) | 2 (5%) | |
| Surgical margin | 26 ± 5.9 | 26 ± 1.3 | 26 ± 4.9 | 0.76 |
|
≤20 mm | 12 (10%) | 8 (8%) | 4 (11%) | |
|
>20 mm | 123 (90%) | 90 (92%) | 33 (89%) |
ALI, adjacent lobe invasion; LLL, left lower lobe; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.
Characteristics of recurrence
| Recurrence | All ( | T‐ALI‐A ( |
T‐ALI‐D ( |
|---|---|---|---|
| Total | 48 (35%) | 42 (43%) | 6 (16%) |
| Loco‐regional | 10 (7%) | 8 (8%) | 2 (5%) |
|
Lung | 2 (1.5%) | 2 (2%) | 0 |
|
Pleura with malignant effusion | 6 (4%) | 5 (5%) | 1 (2.5%) |
|
Lymph node/mediastinum | 2 (1.5%) | 1 (1%) | 1 (2.5%) |
| Distant | 38 (28%) | 34 (35%) | 4 (11%) |
|
Contralateral lung | 4 (3%) | 3 (3%) | 1 (3%) |
|
Contralateral chest wall | 1 (2%) | 1 (1%) | 0 |
|
Brain | 3 (2%) | 2 (2%) | 1 (3%) |
|
Adrenal gland | 4 (3%) | 3 (3%) | 1 (3%) |
|
Liver | 5 (4%) | 4 (4%) | 1 (3%) |
|
Bone | 3 (2%) | 3 (3%) | 0 |
|
Kidney | 4 (3%) | 4 (4%) | 0 |
|
Multiple sites | 3 (2%) | 3 (3%) | 0 |
|
Distant | 11 (6%) | 11 (12%) | 0 |
Figure 3(a) The mean overall survival was 53 ± 3.3 months; (b) T‐ALI‐D showed a significant better survival than T‐ALI‐A (P = 0.01). () T‐ALI‐A, and () T‐ALI‐D.
Figure 4The mean overall survival of patients undergoing () pneumonectomy, () bilobectomy, () lobectomy with segmentectomy, and () lobectomy with wedge resection was 39.8 ± 7.0; 53.9 ± 8.2; 54.3 ± 6.6; and 59.8 ± 4.8, respectively. Comparison of survival curves showed no significant difference (P = 0.09).
Type of resection in relation to pT stage and pN0 stage
| pT Stage (cm) | ||||||
|---|---|---|---|---|---|---|
| pN Stage | Type of resection | ≤3 ( | >3 to 5 ( | >5 to 7 ( | >7 ( | Total |
| pN0 ( | Pneumonectomy | — | — | 1 (2%) | 1 (7%) | 2 (2%) |
| Bilobectomy | 1 (4%) | 7 (16%) | 21 (40%) | 6 (43%) | 35 (36%) | |
| Lobectomy + segmentectomy | 12 (48%) | 5 (12%) | 3 (6%) | 20 (21%) | ||
| Lobectomy + wedge resection | 5 (20%) | 28 (64%) | 6 (12%) | — | 39 (43%) | |
| pN1 ( | Pneumonectomy | — | — | 7 (13%) | 3 (21%) | 10 (67%) |
| Bilobectomy | — | — | 2 (4%) | 0 | 2 (13%) | |
| Lobectomy + segmentectomy | 1 (4%) | 1 (2%) | 0 | — | 2 (13%) | |
| Lobectomy + wedge resection | 1 (4%) | — | — | — | 1 (7%) | |
| pN2 ( | Pneumonectomy | — | — | 7 (13%) | 4 (29%) | 11 (46%) |
| Bilobectomy | — | — | 5 (10%) | 0 | 5 (21%) | |
| Lobectomy + segmentectomy | 1 (4%) | 2 (4%) | — | — | 3 (12%) | |
| Lobectomy + wedge resection | 4 (16%) | 1 (2%) | — | — | 5 (21%) | |
Figure 5No significant difference was observed between patients undergoing () lobectomy with sublobar resections compared to those undergoing () pneumonectomy/bilobectomy in relation to (a) pN0 status (P = 0.52); (b) pN1/pN2 status (P = 0.83); (c) pT ≤5 cm status (P = 0.40); and (d) pT > 5 cm (P = 0.93).
Cox regression analysis (dependent variable: overall survival)
| Univariable | Multivariable | |||||||
|---|---|---|---|---|---|---|---|---|
| Covariates | Coefficient | HR | 95% CI |
| Coefficient | HR | 95% CI |
|
|
| ||||||||
| ≤70 vs. >70 | 0.42 | 1.52 | 0.52–1.34 | 0.19 | — | — | — | — |
|
| ||||||||
| Male vs. female | 0.46 | 1.19 | 0.89–1.78 | 0.65 | — | — | — | — |
|
| ||||||||
| Pneumonectomy/bilobectomy vs. lobectomy with sublobar resection | −0.13 | 0.86 | 0.64–1.56 | 0.75 | — | — | — | — |
|
| ||||||||
| Adenocarcinoma vs. others | 0.76 | 0.45 | 0.75–1.87 | 0.69 | — | — | — | — |
|
| ||||||||
| T‐ALI‐A vs. T‐ALI‐D | 1.3 | 2.13 | 1.1–4.11 | 0.01 | 1.41 | 2.54 | 1.91–4.32 | 0.01 |
|
| ||||||||
| pN0 vs. pN1/pN2 | 1.29 | 3.75 | 1.59–3.45 | 0.0004 | 1.49 | 3.85 | 1.74–3.21 | 0.0002 |
|
| ||||||||
|
| 1.86 | 3.87 | 1.68–2.87 | 0.0001 | 1.86 | 3.91 | 1.68–2.87 | 0.0001 |
|
| ||||||||
| ≤2 cm vs. >2 cm | 0.48 | 0.51 | 0.59–1.35 | 0.37 | ||||
CI, confidence interval at 95%; HR, hazards ratio.